抗长寿型刚地弓形虫疫苗的挑战与策略
本文综述了刚地弓形虫疫苗的研发挑战与策略。自1908年发现该虫以来,全球约三分之一人口暴露,弓形虫病仍是HIV相关机会性中枢神经系统感染之一。文章涵盖传统灭活疫苗至DNA疫苗,讨论构建、佐剂、递送、免疫及模型挑战,并探讨增强策略。
要点
- 全球约三分之一人口暴露于刚地弓形虫,血清阳性率高
- 弓形虫病是HIV相关机会性中枢神经系统感染之一
- 疫苗研发面临构建、佐剂、递送和模型等多重挑战
核心结论
- 有效预防性弓形虫疫苗的开发仍面临多重挑战,需综合优化疫苗构建、佐剂、递送和免疫策略。
研究设计与样本
- 本文为综述,系统梳理从传统灭活全虫疫苗到DNA疫苗等多种弓形虫疫苗研发路径。
主要发现
- 刚地弓形虫生活史复杂,能克服应激并在广泛宿主范围内传播,实现全球高血清阳性率。
- 弓形虫病至今仍是HIV相关机会性中枢神经系统感染之一。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since the discovery of Toxoplasma gondii in 1908, it is estimated that one-third of the global population has been exposed to this ubiquitous intracellular protozoan. The complex life cycle of T. gondii has enabled itself to overcome stress and transmit easily within a broad host range thus achieving a high seroprevalence worldwide. To date, toxoplasmosis remains one of the most prevalent HIV-associated opportunistic central nervous system infections. This review presents a comprehensive overview of different vaccination approaches ranging from traditional inactivated whole-T. gondii vaccines to the popular DNA vaccines. Extensive discussions are made to highlight the challenges in constructing these vaccines, selecting adjuvants as well as delivery methods, immunisation approaches and developing study models. Herein we also deliberate over the latest and promising enhancement strategies that can address the limitations in developing an effective T. gondii prophylactic vaccine.
引用
- Loh FK, Nathan S, Chow SC, et al. Vaccination challenges and strategies against long-lived Toxoplasma gondii. Vaccine. 2019. PMID: 31186188. doi:10.1016/j.vaccine.2019.05.083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。